Open AccessMRI-based Alzheimer’s disease-resemblance atrophy index in the detection of preclinical and prodromal Alzheimer’s disease
Author(s) -
Wanting Liu,
Lisa Au,
Jill Abrigo,
Yishan Luo,
Adrian Wong,
Bonnie Yin Ka Lam,
Xiang Fan,
Pauline Kwan,
Hon Wing Ma,
Anthea Yee Tung Ng,
Sirong Chen,
Ella H. Leung,
Chi Lai Ho,
Shawn Wong,
Winnie Cw Chu,
Ho Ko,
Amy HingLing Lau,
Lin Shi,
Vincent Chung Tong Mok,
Alzheimer’s Disease Neuroimaging Initiative
Publication year - 2021
Publication title -
aging
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.473
H-Index - 90
ISSN - 1945-4589
DOI - 10.18632/aging.203082
Subject(s) - disease , atrophy , medicine , pathology , alzheimer's disease , neuroscience , psychology
Alzheimer's Disease-resemblance atrophy index (AD-RAI) is an MRI-based machine learning derived biomarker that was developed to reflect the characteristic brain atrophy associated with AD. Recent study showed that AD-RAI (≥0.5) had the best performance in predicting conversion from mild cognitive impairment (MCI) to dementia and from cognitively unimpaired (CU) to MCI. We aimed to validate the performance of AD-RAI in detecting preclinical and prodromal AD. We recruited 128 subjects (MCI=50, CU=78) from two cohorts: CU-SEEDS and ADNI. Amyloid (A+) and tau (T+) status were confirmed by PET ( 11 C-PIB, 18 F-T807) or CSF analysis. We investigated the performance of AD-RAI in detecting preclinical and prodromal AD (i.e. A+T+) among MCI and CU subjects and compared its performance with that of hippocampal measures. AD-RAI achieved the best metrics among all subjects (sensitivity 0.74, specificity 0.91, accuracy 85.94%) and among MCI subjects (sensitivity 0.92, specificity 0.81, accuracy 86.00%) in detecting A+T+ subjects over other measures. Among CU subjects, AD-RAI yielded the best specificity (0.95) and accuracy (85.90%) over other measures, while hippocampal volume achieved a higher sensitivity (0.73) than AD-RAI (0.47) in detecting preclinical AD. These results showed the potential of AD-RAI in the detection of early AD, in particular at the prodromal stage.